Achieving target cholesterol levels in diabetic patients: Potency of the statin or potency of the physician?

Israel Medical Association Journal

Volumn 10, Issue 5, 2008, Pages 354-357

  Shani, Michal ^a,b,c   Dresner, Julian ^a,b   Vinker, Shlomo ^a,b  

^a CLALIT HEALTH SERVICES   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c NONE   (Israel)

Author keywords

Daibetes control; Diabetes mellitus; HMG CoA reductase; Low density lipoprotein cholesterol; Primary care

Indexed keywords

ANTIDIABETIC AGENT; CHOLESTEROL; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DIABETES MELLITUS; DIET THERAPY; DRUG POTENCY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PHYSICIAN; PRESCRIPTION; UNSPECIFIED SIDE EFFECT;

AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; ISRAEL; MALE; MIDDLE AGED; PATIENT COMPLIANCE;

EID: 46149096934     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Stern E, Benbassat CA, Nahshoni A, Blum I. Hospitalization for general medical conditions among diabetic patients in Israel. IMAJ 2001;3:21-3.
2. Hogan P, Dall T, Nikolov P. American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care. 2003;26:917-2.
3. Snow V, Aronson MD, Hornbake ER, Mottur-Pilson C, Weiss KB. Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2004;140:644-9.
4. Tovar JM, Bezaldua OV, Poursani RS. LDL levels in diabetes: how low should they go? J Fam Pract 2007;56:634-40
5. Heart Protection Study Collaborative; Mihaylova B, Briggs A, Armitage I, Parish S, Gray A, Collins R. Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived inm a randomised trial of 20,536 people. BMJ 2006; 333:1145.
6. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364:685-96.
7. Knopp RH, d'Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006: 29:1478-85.
8. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39.
9. Anonymous. Standards of medical care in diabetes - 2007. Diabetes Care 2007;30:S4-41.
10. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005;11:449-57.
11. Avogaro A, Guida P, Giorda C, et al. The under-use of statin in type 2 diabetic patients attending diabetic clinics in Italy. Nutr Metab Cardiovasc Dis 2007;17:32-40.
12. Cotton A, Aspy CB, Mold J, Stein H. Clinical decision-making in blood pressure management of patients with diabetes mellitus: an Oklahoma Physicians Resource/Research Network (OKPRN) Study. J Am Board Fam Med 2006;19:232-9.
13. Mottur-Pilson C, Snow V, Bartlett K. Physician explanations for failing to comply with "best practices". Eff Clin Pract 2001:4:207-13.
14. Quality Indicator for Health Care in Israeli 2003-2005 http://www.health.gov.il/dowload/public_report_2006_eng.pdf
15. Grant RW, Buse JB, Meigs JB. University HealthSystem Consortium (UHC) Diabetes Benchmarking Project Team. Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diabetes Care 2005;28:337-42.
16. Cheung RC, Morrell JM, Kallend D, Watkins C, Schuster H. Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study. Int J Cardiol 2005;100:309-16.